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Although there is no doubt that smokers switching to electronic cigarettes (EC) substantially reduce the risk to their
health, some tobacco control activists and health organisations discourage smokers from using EC and lobby policy
makers to reduce EC use by draconian regulation.
The hostility to EC may be related to a moral belief that nicotine use should be eradicated rather than allowed to
morph into a relatively harmless activity. If EC are allowed to compete with cigarettes and develop further, smoking
is likely to all but disappear. Discouraging smokers from making the switch and reducing EC competitiveness with
cigarettes by unwarranted regulation will delay this opportunity or squander it altogether.
In fact, there is now sufficient evidence available for health professionals to recommend to smokers who cannot
stop smoking with existing treatments or do not want to do so, to try several types of e-cigarettes to see if they
can find one meeting their needs.
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Electronic cigarettes controversy
Electronic cigarettes (EC) are a consumer product appea-
ling to smokers looking for a safer way to obtain what they
want from their cigarettes. From what we know about EC
ingredients, toxicology and the chemical and physical pro-
cesses involved, they can be expected, outside pregnancy,
to be at least 95% less harmful than cigarettes [1]. There
is now a sufficient body of evidence available on several
aspects and effects of EC for recent reviews to conclude
that health care professionals and public health bodies
should encourage smokers who cannot stop smoking
using available treatments, or do not want to do so, to
switch to EC [2,3].
Yet at the same time, the World Health Organisation
(WHO) have labelled EC a threat to public health, issued
a strong advice to smokers not to use them [4], and
urges policy makers to limit their use by prohibition or
strict regulation [5]. This and other negative campaigns
are starting to have an alarming effect of persuadingCorrespondence: p.hajek@qmul.ac.uk
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unless otherwise stated.smokers that EC are as harmful as cigarettes [6] and dis-
couraging them from making the switch [7,8].
This commentary argues that EC have a potential to
generate substantial public health benefits and that dis-
couraging smokers from using them and regulating EC
as severely as cigarettes, or even more severely, is detri-
mental to public health.
There are manifest humane and logical reasons to en-
courage smokers who cannot or do not want to stop
smoking but want to limit the damage smoking may do
to their health to switch to EC. Here is the straightfor-
ward case:
There are currently two main products competing for
smokers’ custom. One, the conventional cigarette, is re-
sponsible for disease and premature death in a substan-
tial proportion of its users. It also continues to recruit
new customers from among non-smoking children who
try it. The other, EC, is orders of magnitude safer. On
current evidence it only appeals to smokers and gener-
ates negligible rates of regular use among non-smoking
children who try it. Which one would you prefer your
nicotine addicted father to use? And if your children
were to try a nicotine product, which of these two would
you prefer that they lay their hands on?is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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For the past few years, scientific journals have been pub-
lishing a large volume of commentaries on the EC phe-
nomenon. Most of these focus on hypothetical concerns.
Although all commentators now acknowledge that EC
are safer than cigarettes, EC are typically presented as a
competitor to smoking cessation medications that is pos-
sibly less safe and that can somehow increase cigarette
use, rather than as a consumer product that competes
with cigarettes, and that can make its deadly competi-
tor obsolete.
Some medical organisations which are supposed to
protect public health, such as WHO, go further and ac-
tively discourage smokers from using EC while lobbying
for restricting EC use by regulation. The WHO stance is
underpinned by a review they commissioned [9] that has
been criticised for an unorthodox use of evidence [10]
and illustrates well the anti-EC arguments. Findings that
EC vapour contains traces of toxicants is interpreted as
a sign of danger and even as a threat to bystanders, even
if the levels of these chemicals are well within limits
considered safe in the air we breathe [2,11]. Surveys sho-
wing that a small proportion of children experiment
with EC are presented as a sign of the ‘gateway’ risk des-
pite the fact that virtually no non-smokers progress to
daily EC use and that smoking in youth is declining [12].
Where it fits with the negative agenda, trying EC once
in the past month is labelled as ‘current use’ which by
analogy with ‘current smoking’ is typically interpreted as
daily use. Surveys which include only smokers who did
not find EC helpful and exclude EC users who stopped
smoking are presented as a proof that EC are unhelpful.
‘Dual use’ is presented as a sign of danger despite the
fact that it leads to reduced toxin intake [2]. The toxicity
of nicotine is exaggerated [13] and the evidence that it
makes little if any contribution to smoking related dis-
ease and death [14,15] is ignored. Concerns about the
twisting of evidence for ideological ends have generated
an exchange of letters by large groups of researchers and
activists [16-18]. Given the visibility and influence of the
activists and medical organisations opposing EC use, there
is a risk that these campaigns will discourage or even bar
large numbers of smokers around the world from the un-
questionable benefits of switching from smoking to vap-
ing. Indeed, alarming signs are emerging that smokers
who could benefit from switching to EC now increasingly
believe EC are dangerous and they might as well stick to
the conventional cigarettes [6-8].
Why is there a controversy?
EC are a disruptive technology, threatening sales of to-
bacco products as well as sales of stop smoking medi-
cations and so commercially motivated opposition can
be expected. The hostility to EC from some tobaccocontrol activists, however, is puzzling. Future textbooks
are likely to discuss this phenomenon at length. Here is
one hypothesis.
The field of public health is not always rational. Ideology
and morality can play at least as big a role as evidence and
logic. Public health policies struggle with ideology in areas
ranging from abortion to harm reduction strategies in
drug addiction and sexually transmitted diseases. One of
the possible explanations of the EC controversy is that for
some tobacco control activists, any nicotine use is ‘drug
abuse’ and abhorrent even if it were to carry no physical
health risk. When encountering evidence that EC are
much safer than cigarettes, do not attract non-smokers,
and promise to reduce smoking-related morbidity, people
with this ‘moral stance’ look for objections and counterar-
guments. Evidence is not needed to discover the truth as
the truth is ‘self-evident’ and there is a higher purpose.
Evidence is just a tool to gain converts. Nicotine use
should be eradicated, not allowed to morph into an ac-
tivity akin to drinking coffee. An earlier version of the
WHO Report to the Framework Convention on Tobacco
Control (FCTC), now off-line, betrayed its missionary
ethos when it stated that the group’s target is nicotine ad-
diction (that is, nicotine use) ‘independently from its
source’ (that is, whether it impacts physical health or not).
Nicotine use, of course, can have negative consequen-
ces even if it does not affect physical health. A proportion
of users become dependent. However, compared with dis-
ease and death caused by combustible non-nicotine che-
micals in tobacco smoke, this is a minor consideration.
Worries about nicotine use stripped of the health risks of
smoking are on par with worries about drinking coffee.
Some coffee drinkers do become dependent and spend a
fair amount of money and time on their habit, but this
does not constitute a major public health issue. It defin-
itely does not justify denying smokers health benefits of
stopping smoking just because they would continue to use
nicotine and so their conversion to the true virtue would
be incomplete.
How best to appraise the impact of EC?
Negative expectations and concerns can ultimately prove
to be correct, even if they were generated by irrational
or commercial motives. How should we determine ob-
jectively what impact EC are having on public health?
For a negative impact, EC use would have to generate an
increase in use of cigarettes.
Where commentators worry about gateway effects,
undermining tobacco control achievements or re-
normalisation of smoking, they should be understood
as saying that in their opinion, EC use is generating
or is likely to generate an increase in cigarette consump-
tion. When put like this, it appears a highly improbable
concern. There is no precedent for a safer technology to
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data on this issue are needed.
Emerging trends are as expected. In the UK where
EC are available and taken up by sufficient numbers of
smokers, quit rates are increasing and decline in smoking,
especially among young people, is accelerating [19-21].
The same is happening in the US [12]. In France and Italy
the decline in cigarette sales has been accelerating [22,23].
Such data, of course, cannot determine the cause of these
trends. The sales of EC have so far been too low compared
to sales of cigarettes for their impact to be clearly visible.
More comprehensive studies of the relationship between
sales of cigarettes and sales of EC are currently the num-
ber one research priority. Comparisons are needed of time
trends in sales of cigarettes in countries that allow and
that prohibit EC sales, and sales of cigarettes need to be
plotted against sales of EC over time. This is needed ur-
gently, before the drastic regulation of EC advocated by
the tobacco and pharmaceutical industries and misguided
medical organisations stops the effects of EC sales on
cigarette sales unfolding and hard data emerging which
could provide a rational guidance to policy.Conclusions
Today’s e-cigarettes appeal to only a fraction of the smok-
ing population, but if they are allowed to carry on compet-
ing with cigarettes as a consumer product and innovate
and evolve, there is a good chance that they will continue
to improve in offering smokers what they want, cigarette
sales will continue to fall, and over the next 10 years, in
countries where EC are available and competitively priced,
the use of combustible tobacco will virtually disappear.
The public health benefit would be huge, even if recre-
ational use of nicotine carries on. If, on the other hand,
misleading public health messages discourage smokers
from switching and drastic regulations stop EC evolu-
tion and make them uncompetitive, the opportunity for
a dramatic reduction in smoking related disease and
death will be postponed by many years or even missed
altogether. Future commentators are likely to consider
attempts to remove safer alternatives to cigarettes from
the market unethical, however virtuous the missiona-
ries of the nicotine eradication gospel may feel. In the
meantime, clinicians facing smokers who cannot or do
not want to stop smoking and who follow evidence and
common sense rather than ideologically and commer-
cially driven agendas should recommend that their pa-
tients try several types of e-cigarettes to see if they can
find one meeting their needs.Abbreviations
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